Point: Intensive glycemic control and mortality in ACCORD - A chance finding?

Diabetes Care

Volumn 33, Issue 12, 2010, Pages 2719-2721

  Lachin, John M ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN DERIVATIVE; ROSIGLITAZONE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONSERVATIVE TREATMENT; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG USE; EDITORIAL; FOLLOW UP; GENETIC HETEROGENEITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART DEATH; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INTENSIVE CARE; INTERMETHOD COMPARISON; MAJOR ADVERSE CARDIAC EVENT; MEDICAL CARE; MORTALITY; PATIENT MONITORING; PATIENT SAFETY; PROBABILITY; STROKE; THERAPY EFFECT;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; RISK FACTORS;

EID: 79951714483     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1506     Document Type: Editorial

References (11)

1. Action to Control Cardiovascular Risk in Diabetes Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99 (Suppl.):21i-33i
2. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
3. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-2194
4. Calles-Escandón J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, Bonds DE, Fonseca VA, Ismail- Beigi F, Banerji MA, Failor A, Hamilton B. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010;33:721-727
5. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, Childress RD, Craven TE, Cuddihy RM, Dailey G, Feinglos MN, Ismail-Beigi F, Largay JF, O'Connor PJ, Paul T, Savage PJ, Schubart UK, Sood A, Genuth S; ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010;340:b5444
6. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
7. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, GoffDC Jr, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER, for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-990
8. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44:968-983
9. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412 (Pubitemid 30609442)
10. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial - revisited. Diabetes 2008;57:995-1001
11. Reboussin DM, DeMets DL, Kim KM, Lan KK. Computations for group sequential boundaries using the Lan-DeMets spending function method. Controlled Clinical Trials 2000;21:190-207 (Pubitemid 30259148)